urinary endothelin 1 et 1 concentrations Search Results


quantiglo et 1 kit  (R&D Systems)
94
R&D Systems quantiglo et 1 kit
Quantiglo Et 1 Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Human+Endothelin-1+QuantiGlo+ELISA+Kit/pmc07099501-203-7-10
Average 94 stars, based on 1 article reviews
quantiglo et 1 kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
urinary endothelin 1 et 1 concentrations  (R&D Systems)
96
R&D Systems urinary endothelin 1 et 1 concentrations
Urinary Endothelin 1 Et 1 Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Endothelin-1+Quantikine+ELISA+Kit/pmc07772288-59-0-11
Average 96 stars, based on 1 article reviews
urinary endothelin 1 et 1 concentrations - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
human endothelin-1 quantiglo elisa kit  (Bio-Techne corporation)
94
Bio-Techne corporation human endothelin-1 quantiglo elisa kit
Human Endothelin 1 Quantiglo Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Human+Endothelin-1+QuantiGlo+ELISA+Kit/custom%40qet00b%4036733911
Average 94 stars, based on 1 article reviews
human endothelin-1 quantiglo elisa kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
endothelin-1 quantikine elisa kit  (Bio-Techne corporation)
96
Bio-Techne corporation endothelin-1 quantikine elisa kit
Endothelin 1 Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Endothelin-1+Quantikine+ELISA+Kit/custom%40det100%4028805977
Average 96 stars, based on 1 article reviews
endothelin-1 quantikine elisa kit - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
odyssey  (LI-COR)
99
LI-COR odyssey
Odyssey, supplied by LI-COR, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Odyssey/custom%40Odyssey%4010%2E1161%2Fhypertensionaha%2E110%2E157685
Average 99 stars, based on 1 article reviews
odyssey - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
odyssey imaging system  (LI-COR)
99
LI-COR odyssey imaging system
Odyssey Imaging System, supplied by LI-COR, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/Odyssey+Imaging+System/custom%40odyssey-imaging-system%4010%2E1161%2Fhypertensionaha%2E110%2E157685
Average 99 stars, based on 1 article reviews
odyssey imaging system - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
urinary neutrophil gelatinase-associated lipocalcin ngal  (BioPorto Inc)
90
BioPorto Inc urinary neutrophil gelatinase-associated lipocalcin ngal
Biochemical Markers of AKI. (A) Creatinine clearance, an index of GFR, as per Figure A. (B) IL-6, a serum biomarker of AKI, (C) Serum Creatinine, (D) IUrinary <t>Neutrophil</t> Gelatinase-Associated <t>Lipocalcin</t> (NGAL), a urinary AKI biomarker . Values represent mean (SEM) at least n = 6 per group. (E) Immunofluorescence for tubular Endothelin-1 expression at 24 Hours post Intervention, quantified by Western Blotting and densitometry as described. Values represent mean (SEM) at least n = 6 per group. * p <0.05 versus sham, † p <0.05 versus Sham+HF, ‡ p <0.05 versus CPB. For graphs pooled estimates for pairwise comparisons derived from Analysis of Covariance with adjustment for baseline Creatinine Clearance estimated at 114 ml/min, serum creatinine 135 µmol/L, serum IL-6 estimated at 18.6 pg/ml, urinary NGAL creatinine ratio estimated at 3.69 ng/µmol, were as follows: Creatinine Clearance; Post CPB Intervention: Sham- Sham + HF, 25.9 ml/min (95% CI -19.4 to 71.1), p = 0.249, Sham-CPB 50.2 ml/min (95% CI 5.9 to 94.4), p = 0.028, Sham-CPB + HF 52.9, (95% CI 7.1 to 98.6), p = 0.026. Test for overall treatment effect p = 0.079. Day 1 Post intervention: Sham-Sham+HF, -14.8 ml/min (95% CI 56.7 to 27.1), p = 472, Sham-CPB 42.7 ml/min (95% CI 3.8 to 81.5), p = 0.033, Sham-CPB + HF -22.6 ml/min, (95% CI -65.0 to 19.7), p = 0.280, CPB-CPB + HF -65.3 ml/min (95% CI -106.9 to -23.7) p = 0.004. Test for overall treatment effect p <0.001. Serum Creatinine; Post CPB Intervention: Sham-Sham + HF, -9.5 µmol/L (95% CI -17.2 to -1.7), p = 0.019, Sham-CPB -9.9 µmol/L (95% CI -17.5 to -2.4), p = 0.012, Sham-CPB + HF -11.9 µmol/L, (95% CI -20.1 to -3.9), p = 0.006. Test for overall treatment effect p = 0.017. Day 1 Post intervention: Test for overall treatment effect p = 0.788. Serum IL-6; Post Intervention: Sham-Sham + HF -1.5 pg/ml (95% CI -9.3 to 6.4), p = 0.701, Sham-CPB -11.3 (95% CI -19.6 to -3.2), p = 0.009, Sham-CPB + HF -3.5, (95% CI -12.1 to 5.0), p = 0.399. Test for overall treatment effect p = 0.039. Day 1 Post Intervention: Sham-Sham + HF, -1.0 pg/ml (95% CI -3.7 to 1.7), p = 0.433, Sham-CPB -5.9 pg/ml (95% CI -8.7 to -3.2), p <0.001, Sham-CPB + HF -2.1 pg/ml, (95% CI -4.9 to 0.83), p = 0.153. Test for overall treatment effect p = 0.001. Urinary NGAL/ Creatinine Ratio; Post Intervention: Sham-Sham + HF, 0.11 (95% CI 0.04 to 0.37), p = 0.001, Sham-CPB 0.16 (95% CI 0.04 to 0.66), p = 0.014, Sham-CPB + HF 0.09, (95% CI 0.02 to 0.40). Test for overall treatment effect p = 0.004. Day 1 Post Intervention: Test for overall treatment effect p = 0.601.
Urinary Neutrophil Gelatinase Associated Lipocalcin Ngal, supplied by BioPorto Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/urinary+endothelin+1+et+1+concentrations/neutrophil+gelatinase+associated+lipocalin++ngal/pmc04056797-73-22-26
Average 90 stars, based on 1 article reviews
urinary neutrophil gelatinase-associated lipocalcin ngal - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Biochemical Markers of AKI. (A) Creatinine clearance, an index of GFR, as per Figure A. (B) IL-6, a serum biomarker of AKI, (C) Serum Creatinine, (D) IUrinary Neutrophil Gelatinase-Associated Lipocalcin (NGAL), a urinary AKI biomarker . Values represent mean (SEM) at least n = 6 per group. (E) Immunofluorescence for tubular Endothelin-1 expression at 24 Hours post Intervention, quantified by Western Blotting and densitometry as described. Values represent mean (SEM) at least n = 6 per group. * p <0.05 versus sham, † p <0.05 versus Sham+HF, ‡ p <0.05 versus CPB. For graphs pooled estimates for pairwise comparisons derived from Analysis of Covariance with adjustment for baseline Creatinine Clearance estimated at 114 ml/min, serum creatinine 135 µmol/L, serum IL-6 estimated at 18.6 pg/ml, urinary NGAL creatinine ratio estimated at 3.69 ng/µmol, were as follows: Creatinine Clearance; Post CPB Intervention: Sham- Sham + HF, 25.9 ml/min (95% CI -19.4 to 71.1), p = 0.249, Sham-CPB 50.2 ml/min (95% CI 5.9 to 94.4), p = 0.028, Sham-CPB + HF 52.9, (95% CI 7.1 to 98.6), p = 0.026. Test for overall treatment effect p = 0.079. Day 1 Post intervention: Sham-Sham+HF, -14.8 ml/min (95% CI 56.7 to 27.1), p = 472, Sham-CPB 42.7 ml/min (95% CI 3.8 to 81.5), p = 0.033, Sham-CPB + HF -22.6 ml/min, (95% CI -65.0 to 19.7), p = 0.280, CPB-CPB + HF -65.3 ml/min (95% CI -106.9 to -23.7) p = 0.004. Test for overall treatment effect p <0.001. Serum Creatinine; Post CPB Intervention: Sham-Sham + HF, -9.5 µmol/L (95% CI -17.2 to -1.7), p = 0.019, Sham-CPB -9.9 µmol/L (95% CI -17.5 to -2.4), p = 0.012, Sham-CPB + HF -11.9 µmol/L, (95% CI -20.1 to -3.9), p = 0.006. Test for overall treatment effect p = 0.017. Day 1 Post intervention: Test for overall treatment effect p = 0.788. Serum IL-6; Post Intervention: Sham-Sham + HF -1.5 pg/ml (95% CI -9.3 to 6.4), p = 0.701, Sham-CPB -11.3 (95% CI -19.6 to -3.2), p = 0.009, Sham-CPB + HF -3.5, (95% CI -12.1 to 5.0), p = 0.399. Test for overall treatment effect p = 0.039. Day 1 Post Intervention: Sham-Sham + HF, -1.0 pg/ml (95% CI -3.7 to 1.7), p = 0.433, Sham-CPB -5.9 pg/ml (95% CI -8.7 to -3.2), p <0.001, Sham-CPB + HF -2.1 pg/ml, (95% CI -4.9 to 0.83), p = 0.153. Test for overall treatment effect p = 0.001. Urinary NGAL/ Creatinine Ratio; Post Intervention: Sham-Sham + HF, 0.11 (95% CI 0.04 to 0.37), p = 0.001, Sham-CPB 0.16 (95% CI 0.04 to 0.66), p = 0.014, Sham-CPB + HF 0.09, (95% CI 0.02 to 0.40). Test for overall treatment effect p = 0.004. Day 1 Post Intervention: Test for overall treatment effect p = 0.601.

Journal: Critical Care

Article Title: High fat feeding promotes obesity and renal inflammation and protects against post cardiopulmonary bypass acute kidney injury in swine

doi: 10.1186/cc13092

Figure Lengend Snippet: Biochemical Markers of AKI. (A) Creatinine clearance, an index of GFR, as per Figure A. (B) IL-6, a serum biomarker of AKI, (C) Serum Creatinine, (D) IUrinary Neutrophil Gelatinase-Associated Lipocalcin (NGAL), a urinary AKI biomarker . Values represent mean (SEM) at least n = 6 per group. (E) Immunofluorescence for tubular Endothelin-1 expression at 24 Hours post Intervention, quantified by Western Blotting and densitometry as described. Values represent mean (SEM) at least n = 6 per group. * p <0.05 versus sham, † p <0.05 versus Sham+HF, ‡ p <0.05 versus CPB. For graphs pooled estimates for pairwise comparisons derived from Analysis of Covariance with adjustment for baseline Creatinine Clearance estimated at 114 ml/min, serum creatinine 135 µmol/L, serum IL-6 estimated at 18.6 pg/ml, urinary NGAL creatinine ratio estimated at 3.69 ng/µmol, were as follows: Creatinine Clearance; Post CPB Intervention: Sham- Sham + HF, 25.9 ml/min (95% CI -19.4 to 71.1), p = 0.249, Sham-CPB 50.2 ml/min (95% CI 5.9 to 94.4), p = 0.028, Sham-CPB + HF 52.9, (95% CI 7.1 to 98.6), p = 0.026. Test for overall treatment effect p = 0.079. Day 1 Post intervention: Sham-Sham+HF, -14.8 ml/min (95% CI 56.7 to 27.1), p = 472, Sham-CPB 42.7 ml/min (95% CI 3.8 to 81.5), p = 0.033, Sham-CPB + HF -22.6 ml/min, (95% CI -65.0 to 19.7), p = 0.280, CPB-CPB + HF -65.3 ml/min (95% CI -106.9 to -23.7) p = 0.004. Test for overall treatment effect p <0.001. Serum Creatinine; Post CPB Intervention: Sham-Sham + HF, -9.5 µmol/L (95% CI -17.2 to -1.7), p = 0.019, Sham-CPB -9.9 µmol/L (95% CI -17.5 to -2.4), p = 0.012, Sham-CPB + HF -11.9 µmol/L, (95% CI -20.1 to -3.9), p = 0.006. Test for overall treatment effect p = 0.017. Day 1 Post intervention: Test for overall treatment effect p = 0.788. Serum IL-6; Post Intervention: Sham-Sham + HF -1.5 pg/ml (95% CI -9.3 to 6.4), p = 0.701, Sham-CPB -11.3 (95% CI -19.6 to -3.2), p = 0.009, Sham-CPB + HF -3.5, (95% CI -12.1 to 5.0), p = 0.399. Test for overall treatment effect p = 0.039. Day 1 Post Intervention: Sham-Sham + HF, -1.0 pg/ml (95% CI -3.7 to 1.7), p = 0.433, Sham-CPB -5.9 pg/ml (95% CI -8.7 to -3.2), p <0.001, Sham-CPB + HF -2.1 pg/ml, (95% CI -4.9 to 0.83), p = 0.153. Test for overall treatment effect p = 0.001. Urinary NGAL/ Creatinine Ratio; Post Intervention: Sham-Sham + HF, 0.11 (95% CI 0.04 to 0.37), p = 0.001, Sham-CPB 0.16 (95% CI 0.04 to 0.66), p = 0.014, Sham-CPB + HF 0.09, (95% CI 0.02 to 0.40). Test for overall treatment effect p = 0.004. Day 1 Post Intervention: Test for overall treatment effect p = 0.601.

Article Snippet: Levels of inflammation were determined by measurement of endothelin-1 (ET-1) levels in renal tissue as described below, and the measurement of urinary neutrophil gelatinase-associated lipocalcin (NGAL; Bioporto Diagnostics A/S, Gentofte, Denmark) and serum interleukin (IL)-6 (Invitrogen, Paisley, UK) using enzyme-linked immunosorbent assay.

Techniques: Biomarker Discovery, Immunofluorescence, Expressing, Western Blot, Derivative Assay